These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 37444515)

  • 1. Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9.
    Chan C; Lustig M; Jansen JHM; Garcia Villagrasa L; Raymakers L; Daamen LA; Valerius T; van Tetering G; Leusen JHW
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
    Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
    Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity.
    Bouti P; Blans C; Klein BJAM; Shome D; Nadafi R; Van Houdt M; Schornagel K; Verkuijlen PJJH; Roos V; Reijmers RM; Van Bruggen R; Kuijpers TW; Matlung HL
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38138970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
    Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
    Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing IgA-mediated neutrophil cytotoxicity against neuroblastoma by CD47 blockade.
    Chan C; Stip M; Nederend M; Jansen M; Passchier E; van den Ham F; Wienke J; van Tetering G; Leusen J
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Siglec-5 is an inhibitory immune checkpoint molecule for human T cells.
    Vuchkovska A; Glanville DG; Scurti GM; Nishimura MI; White P; Ulijasz AT; Iwashima M
    Immunology; 2022 Jun; 166(2):238-248. PubMed ID: 35290663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells.
    Martínez-Sanz P; Hoogendijk AJ; Verkuijlen PJJH; Schornagel K; van Bruggen R; van den Berg TK; Tytgat GAM; Franke K; Kuijpers TW; Matlung HL
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Siglec Signaling in the Tumor Microenvironment.
    van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
    Front Immunol; 2021; 12():790317. PubMed ID: 34966391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils.
    Behrens LM; van den Berg TK; van Egmond M
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy.
    Chan C; Cabanes NC; Jansen JHM; Guillaume J; Nederend M; Passchier EM; Gómez-Mellado VE; Peipp M; Boes M; van Tetering G; Leusen JHW
    Cancer Immunol Immunother; 2024 Oct; 73(12):238. PubMed ID: 39358557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
    Bärenwaldt A; Läubli H
    Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
    [No Abstract]   [Full Text] [Related]  

  • 12. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.
    Ibarlucea-Benitez I; Weitzenfeld P; Smith P; Ravetch JV
    Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34155121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?
    Chan C; Lustig M; Baumann N; Valerius T; van Tetering G; Leusen JHW
    Front Immunol; 2022; 13():932155. PubMed ID: 35865547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7.
    van Houtum EJH; Kers-Rebel ED; Looman MW; Hooijberg E; Büll C; Granado D; Cornelissen LAM; Adema GJ
    Cell Mol Life Sci; 2023 May; 80(6):169. PubMed ID: 37253806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
    Daly J; Carlsten M; O'Dwyer M
    Front Immunol; 2019; 10():1047. PubMed ID: 31143186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
    Boelaars K; van Kooyk Y
    Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities.
    Haas Q; Markov N; Muerner L; Rubino V; Benjak A; Haubitz M; Baerlocher GM; Ng CKY; Münz C; Riether C; Ochsenbein AF; Simon HU; von Gunten S
    Front Immunol; 2022; 13():996746. PubMed ID: 36211376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
    van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
    Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tools to study and target the Siglec-sialic acid axis in cancer.
    Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
    FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.
    Läubli H; Pearce OM; Schwarz F; Siddiqui SS; Deng L; Stanczak MA; Deng L; Verhagen A; Secrest P; Lusk C; Schwartz AG; Varki NM; Bui JD; Varki A
    Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14211-6. PubMed ID: 25225409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.